1.39
-0.025(-1.77%)
Currency In USD
Address
75/76 Wimpole Street
London, W1G 9RT
United Kingdom of Great Britain and Northern Ireland
Phone
44 20 8004 0270
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
January 06, 2014
| Name | Title | Pay | Year Born |
| Mr. Abizer Gaslightwala | Chief Executive Officer, President & Director | 1,796 | 1974 |
| Dr. Torsten Hombeck Ph.D. | Chief Financial Officer | 290,700 | 1970 |
| Mr. Mark F. Kubik M.B.A. | Head of Business Development - Oncology | 0 | 1965 |
| Dr. Miles Nunn | Chief Scientific Officer | 0 | 1970 |
| Dr. Satyajit Mitra Ph.D. | Executive Director & Head of Oncology | 0 | 1975 |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.